title: Single nucleotide polymorphisms in the Anti-Müllerian hormone (AMH Ile(49)Ser) and Anti-Müllerian hormone type II receptor (AMHRII -482 A>G) as genetic markers in assisted reproduction technology.
abstract: OBJECTIVE
  The aim of the study was to evaluate whether the presence Antimullerian hormone (AMH) and Antimullerian hormone type II receptor (AMHRII) single nucleotide polymorphisms (SNPs) Ile(49)Ser and -482A>G respectively are related to the assisted reproduction outcome.
  
  
  METHODS
  A prospective cross-sectional observational study was conducted in order to assess the distribution of AMH and AMHRII SNPs in two cohorts, one of healthy women (N = 100) and the control group and the IVF/ICSI group (N = 151) consisted of women undergoing IVF/ICSI treatment for infertility. Furthermore, a prospective longitudinal observational study was performed on the latter group to assess possible associations of these SNPs with patients' characteristics and controlled ovarian stimulation (COS) and pregnancy outcome.
  
  
  RESULTS
  Among non-carriers of the AMH (Ile(49)Ser) polymorphism, basal FSH levels were lower in those with more than two of previous IVF attempts and fertilization rate was statistically higher in those with peak serum E2 levels below 1500 pg/ml, whereas among non-carriers of the AMHRII (-482 A>G) polymorphism, number of follicles was higher in those with more than two previous IVF attempts and total dose of gonadotropins was lower in those with peak serum E2 levels above 1500 pg/ml.
  
  
  CONCLUSIONS
  There was evidence that in specific subgroups of women undergoing IVF/ICSI, AMH and AMHRII SNPs may be related to patients' characteristics and controlled ovarian stimulation and pregnancy outcome and thus may provide a means for the prediction of ovarian response in specific subgroups of women entering an IVF/ICSI program.
authors.affiliation: Molecular Biology Unit, Division of Human Reproduction, 1st Department of Obstetrics and Gynaecology, Alexandra Hospital, Athens University Medical School, 80 Vasilissis Sofias Av, 11528, Athens, Greece, iro.karagiorga@yahoo.com.
authors.forename: Iro
authors.initials: I
authors.lastname: Karagiorga
authors.forename: George A
authors.initials: GA
authors.lastname: Partsinevelos
authors.forename: Despina
authors.initials: D
authors.lastname: Mavrogianni
authors.forename: Elli
authors.initials: E
authors.lastname: Anagnostou
authors.forename: Ioannis
authors.initials: I
authors.lastname: Zervomanolakis
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Kallianidis
authors.forename: Petros
authors.initials: P
authors.lastname: Drakakis
authors.forename: Dimitris
authors.initials: D
authors.lastname: Loutradis
mesh_terms: D000328:Adult; D054304:Anti-Mullerian Hormone / Q000235:genetics*; D005260:Female; D005307:Fertilization in Vitro; D005819:Genetic Markers; D006801:Humans; D010062:Ovulation Induction; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D011247:Pregnancy; D011256:Pregnancy Outcome / Q000235:genetics; D018000:Receptors, Peptide / Q000235:genetics*; D018125:Receptors, Transforming Growth Factor beta / Q000235:genetics*; D027724:Reproductive Techniques, Assisted
chemical_list: D005819:Genetic Markers; D018000:Receptors, Peptide; D018125:Receptors, Transforming Growth Factor beta; C084621:anti-Mullerian hormone receptor; D054304:Anti-Mullerian Hormone